1 not yet recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Mitomycin C (MMC): new trials by email Literature Review of Mitomycin C (MMC) trials Research Report on Mitomycin C (MMC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study Toripalimab, Gemcitabine (GEM), Mitomycin C (MMC) - Urinary Bladder Neoplasms, Carcinoma, Transitional Cell | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 106 | 2026-12-01 | 2026-09-08 |
| Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer Disitamab Vedotin, Mitomycin C (MMC) - Non-Muscle-Invasive Bladder Cancer (NMIBC) | Phase 2 | Recruiting | Shanxi Province Cancer Hospital | 30 | 2024-04-01 | 2026-06-12 |
Non-Muscle Invasive Bladder Neoplasms (2) · Carcinoma in Situ (1) · Carcinoma, Transitional Cell (1) · Urinary Bladder Neoplasms (1)
First Affiliated Hospital of Wenzhou Medical University (1) · Shanxi Province Cancer Hospital (1)
China (2)
PMID 19171491, PMID 23510863, PMID 34051177, PMID 37596191, PMID 38265030, PMID 38740030